改善心血管疾病防治现状,一直在路上——马长生教授

doi:10.3969/j.issn.1006-7795.2020.05.021

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (5): 834-838.doi: 10.3969/j.issn.1006-7795.2020.05.021

改善心血管疾病防治现状,一直在路上——马长生教授

贾朝旭, 马长生

国家心血管疾病临床医学研究中心首都医科大学附属北京安贞医院, 北京 100029

收稿日期:2020-08-28 出版日期:2020-10-21 发布日期:2020-10-26
通讯作者: 马长生 E-mail:chshma@vip.sina.com

Dedication to advancing the prevention and management of cardiovascular diseases——Professor Ma Changsheng

Jia Zhaoxu, Ma Changsheng

National Clinical Research Center for Cardiovascular Diseases;Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Received:2020-08-28 Online:2020-10-21 Published:2020-10-26

摘要/Abstract

摘要： 马长生，首都医科大学附属北京安贞医院心脏内科中心主任，北京学者，一直致力于改善我国心血管疾病的防治现状，尤其为我国心律失常领域的防治做出了重要的贡献。

关键词: 心房颤动, 临床研究, 心血管疾病预防

Abstract: Professor Ma Changsheng has been dedicated to advancing the prevention and management of cardiovascular diseases and has made great contributions to the prevention and management of arrhythmia in China.

Key words: atrial fibrillation, clinical research, cardiovascular disease prevention

中图分类号:

贾朝旭, 马长生. 改善心血管疾病防治现状,一直在路上——马长生教授[J]. 首都医科大学学报, 2020, 41(5): 834-838.

Jia Zhaoxu, Ma Changsheng. Dedication to advancing the prevention and management of cardiovascular diseases——Professor Ma Changsheng[J]. Journal of Capital Medical University, 2020, 41(5): 834-838.

参考文献

[1] Morin D P, Bernard M L, Madias C, et al. The state of the art:atrial fibrillation epidemiology, prevention, and treatment[J]. Mayo Clin Proc,2016,91(12):1778-1810.
[2] Odutayo A, Wong C X, Hsiao A J, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death:systematic review and meta-analysis[J]. BMJ,2016,354:i4482.
[3] Knecht S, Hocini M, Wright M, et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation[J]. Eur Heart J,2008,29(19):2359-2366.
[4] Rostock T, Steven D, Hoffmann B, et al. Chronic atrial fibrillation is a biatrial arrhythmia:data from catheter ablation of chronic atrial fibrillation aiming arrhythmia termination using a sequential ablation approach[J]. Circ Arrhythm Electrophysiol,2008,1(5):344-353.
[5] Dong J Z, Sang C H, Yu R H, et al. Prospective randomized comparison between a fixed ‘2C3L’ approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation[J]. Europace,2015,17(12):1798-1806.
[6] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678.
[7] January C T, Wann L S, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2019,74(1):104-132.
[8] Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation:results of the ADVANCE study[J]. Eur Heart J,2009,30(9):1128-1135.
[9] Soliman E Z, Safford M M, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction[J]. JAMA Intern Med,2014,174(1):107-114.
[10] Catapano A L, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. Atherosclerosis,2016,253:281-344.
[11] Xia S J, Du X, Li C, et al. Uptake of evidence-based statin therapy among atrial fibrillation patients in China:A report from the CAFR (Chinese Atrial Fibrillation Registry) Study[J]. Int J Cardiol,2016,220:284-289.
[12] Jiang C, Lan D H, Du X, et al. Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation:A report from the China atrial fibrillation registry study[J]. J Cardiovasc Electrophysiol,2019,30(12):2759-2766.
[13] Chen Y W, Bai R, Lin T, et al. Pacing or ablation:which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?[J]. Pacing Clin Electrophysiol,2014,37(4):403-411.
[14] Du X, Patel A, Anderson C S, et al. Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement:JACC International[J]. J Am Coll Cardiol,2019,73(24):3135-3147.
[15] Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease?[J]. J Am Coll Cardiol,2017,69(15):1968-1982.

改善心血管疾病防治现状,一直在路上——马长生教授

Dedication to advancing the prevention and management of cardiovascular diseases——Professor Ma Changsheng

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	赵继宗. 我国脑心血管共患疾病现状与临床研究[J]. 首都医科大学学报, 2022, 43(5): 671-673.
[2]	岳小林, 李晓玲, 王美霞, 白桦, 张卓然, 王香平. 北京市医学伦理审查互认现场督导检查评分标准的制订与初步应用[J]. 首都医科大学学报, 2022, 43(4): 664-668.
[3]	喻荣辉, 汤日波, 吴嘉慧, 闻松男, 林晖. 肾移植病史心房颤动患者导管消融的安全性及有效性分析[J]. 首都医科大学学报, 2020, 41(3): 433-438.
[4]	张杨, 马展鸿, 蒋涛. 心房颤动患者左房耳形态与血栓及短暂性脑缺血发作关系的研究[J]. 首都医科大学学报, 2019, 40(5): 776-780.
[5]	段彦龙, 金玲, 杨菁, 黄爽, 张梦, 赖瑞, 周春菊, 张永红. 儿童伯基特白血病26例临床研究[J]. 首都医科大学学报, 2016, 37(2): 141-147.
[6]	林涛, 魏欣, 徐晓薇, 马岩, 王蕊, 田俊萍, 郭晓彬, 陈步星. 可调弯鞘在心房颤动环肺静脉隔离术中的应用经验[J]. 首都医科大学学报, 2016, 37(1): 54-57.
[7]	张振华, 张海波, 韩建成, 孟旭, 韩杰, 李岩, 王刚. 外科微创手术治疗心房颤动对左心房功能的影响[J]. 首都医科大学学报, 2015, 36(3): 371-375.
[8]	王唯坚, 胡峻. 155例非酒精性脂肪肝患者的中医证候学研究[J]. 首都医科大学学报, 2014, 35(1): 129-131.
[9]	穆利英;杜凤和;徐秀英. 非瓣膜性心房颤动患者脑卒中危险因素的临床分析[J]. 首都医科大学学报, 2006, 27(3): 375-378.
[10]	李梅;华琦;刘荣坤;杨铮. 高血压合并心房颤动对内皮细胞功能的影响[J]. 首都医科大学学报, 2005, 26(3): 312-315.
[11]	王长华;胡大一;汤楚中;吴明营;梅运清. 慢性心房颤动患者右心耳IL-1β、IL-6和肿瘤坏死因子-α基因表达的研究[J]. 首都医科大学学报, 2005, 26(2): 111-115.
[12]	孙异临;张辉;曲宝清;王忠诚;张俊庭. 颅底脊索瘤的超微结构与临床的相关研究[J]. 首都医科大学学报, 2003, 24(1): 60-63.
[13]	李光美;丁五麟. 老年人冠心病房颤与左房内径关系的探讨[J]. 首都医科大学学报, 1997, 18(2): 122-124.